Skip to main content

Table 2 Patient survival according to BCLC stage and treatment

From: Octreotide treatment of patients with hepatocellular carcinoma - a retrospective single centre controlled study

  

BCLC A

BCLC B

  

number

median survival (months)

log rank test

number

median survival (months)

log rank test

number treatment modalities

 

40

  

55

  
 

Sandostatin LAR

11

31.4

P = 0.35038

14

22.4

P = 0.00003

 

TACE

5

37.3

 

9

22.0

 
 

multimodal therapy

7

40.2

 

10

35.5

 
 

palliative care

17

15.1

 

22

2.9